GeoVax Labs, Inc. — Q2 2014 Form 10-Q
Business context and reporting period. GeoVax is a development-stage biotechnology company focused on preventive and therapeutic HIV vaccines. This unaudited report covers the quarter and six months ended June 30, 2014. The company had no approved products or product sales; reported revenue was NIH grant revenue.
Financial performance and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Grant revenue | 2014: $180,441; 2013: $441,561 | 2014: $337,781; 2013: $1,238,601 |
| Research and development expense | 2014: $516,202; 2013: $553,199 | 2014: $919,062; 2013: $1,435,187 |
| General and administrative expense | 2014: $344,862; 2013: $415,784 | 2014: $716,664; 2013: $1,028,727 |
| Net loss | 2014: $679,537; 2013: $526,284 | 2014: $1,295,455; 2013: $1,223,081 |
| Loss per common share | 2014: $0.03; 2013: $0.02 | 2014: $0.05; 2013: $0.06 |
- At June 30, 2014, cash and cash equivalents were $1.37 million, down from $2.51 million at December 31, 2013. Working capital was $1.16 million, versus $2.39 million at year-end; total assets were $1.52 million.
- For the first half, operating cash use was $1.13 million, compared with $798,000 in 2013. Investing cash use was $11,164; there were no financing cash proceeds, compared with $1.64 million from stock warrant exercises in the prior-year period.
- Current liabilities were $237,494, including $111,200 payable to related party Emory University. The filing reports no long-term debt, committed credit lines, or other committed funding. No material market-risk exposure was identified.
- Operating margins are not meaningfully comparable because revenue consists of grants recognized as related costs are incurred; the filing does not present a conventional product gross margin.
Changes versus the prior comparable period
- First-half grant revenue fell to $338,000 from $1.24 million, principally reflecting lower grant-related expenditures and their timing. R&D expense decreased 36%, while G&A expense decreased 30%.
- Despite lower operating expenses, the first-half net loss widened to $1.30 million from $1.22 million. Second-quarter net loss also increased year over year.
- Cash used in operations rose by approximately $333,000 year over year. The company ended June with $1.14 million less cash than at the start of 2014.
- During the first half, preferred-stock conversions issued 202,857 common shares from Series A and 1.2 million from Series B. Series A was fully converted; remaining Series B shares were convertible into approximately 3.51 million common shares at June 30.
Outlook, risks, and notable items
- Management said existing cash and expected NIH grant proceeds would fund planned operations into the first quarter of 2015. Additional capital would be needed thereafter; the company planned to seek grants and clinical-trial support and pursue equity offerings, with no assurance funding would be available on acceptable terms.
- The NIH IPCAVD grant had approximately $484,500 remaining at June 30, available through August 31, 2014. In July, NIH awarded approximately $290,000 for the second year of an SBIR project.
- Management expected a preventive-vaccine Phase 2b efficacy trial to begin in late 2015 or early 2016, subject to HVTN/NIH planning and support. Additional vaccine manufacturing was estimated to cost approximately $3 million. A planned HIV immunotherapy Phase 1/2 trial was estimated to cost $2–3 million and depends on securing funding.
- Key risks include financing shortfalls, clinical or regulatory failure, uncertain government support, and the long and costly path to commercialization. Management expected continuing losses and stated that insufficient funding could force research delays, reductions, or termination. No material changes to previously disclosed risk factors were reported.
- Subsequent events included 250,000 common shares issued in July for consulting services, with $50,000 compensation expense, and 50,000 shares issued in August upon Series B conversion. Lease and other firm purchase commitments totaled approximately $90,000 at June 30.
- The company adopted ASU 2014-10 effective June 30, 2014, stating that it materially affected the financial statements. Management assessed disclosure controls as effective; no material internal-control changes or legal proceedings were reported.
Important facts for investors to verify
- Whether additional financing and NIH/HVTN support are secured, and how long available cash will fund operations.
- Whether the remaining IPCAVD funds were used by the grant’s August 31, 2014 end date and how the second-year SBIR award is applied.
- Progress, timing, funding, and expected company costs for the planned clinical trials and vaccine manufacturing.
- Potential dilution from Series B conversion, outstanding warrants, options, and subsequent share issuances. The filing reports 25,468,037 common shares outstanding as of August 8, 2014.